The IL13α 2R paves the way for anti-glioma nanotherapy

Ilya V. Ulasov; Anton Borovjagin; Anastasia Laevskaya; Margarita Kamynina; Peter Timashev; Laura Cerchia; Elena A. Rozhkova

doi:10.1016/j.gendis.2021.08.006

您当前的位置：

首页 >

文章列表页 >

The IL13α 2R paves the way for anti-glioma nanotherapy

更新时间：2023-08-29

- The IL13α 2R paves the way for anti-glioma nanotherapy
- Genes & Diseases Vol. 10, Issue 1, (2023)
- 作者机构：
  
  1. Group of Experimental Biotherapy and Diagnostic, Institute for Regenerative Medicine, World-Class Research Center “Digital Biodesign and Personalized Healthcare”, Sechenov First Moscow State Medical University (Sechenov University), 8-2 Trubetskaya St.,Moscow,Russia,119991
  2. Department of BioMedical Engineering, University of Alabama at Birmingham,AL,Birmingham,USA,35294
  3. Institute for Regenerative Medicine, World-Class Research Center “Digital Biodesign and Personalized Healthcare”, Sechenov First Moscow State Medical University (Sechenov University), 8-2 Trubetskaya St.,Moscow,Russia,119991
  4. Department of Polymers and Composites, N.N. Semenov Institute of Chemical Physics, 4 Kosygin St,Moscow,Russia,119991
  5. Chemistry Department, Lomonosov Moscow State University, Leninskiye Gory 1-3,Moscow,Russia,119991
  6. Institute of Experimental Endocrinology and Oncology “G. Salvatore” (IEOS), National Research Council (CNR),Naples,Italy,80131
  7. Center for Nanoscale Materials, Argonne National Laboratory, Argonne,IL,USA,60439
- 作者简介：
- 基金信息：
- DOI：10.1016/j.gendis.2021.08.006
  CLC：
- Published：2023，
  
  Published Online：1 January 2023，
扫描看全文
Ilya V. Ulasov, Anton Borovjagin, Anastasia Laevskaya, et al. The IL13α 2R paves the way for anti-glioma nanotherapy. [J]. Genes & Diseases 10(1).(2023)
DOI：

Ilya V. Ulasov, Anton Borovjagin, Anastasia Laevskaya, et al. The IL13α 2R paves the way for anti-glioma nanotherapy. [J]. Genes & Diseases 10(1).(2023) DOI： 10.1016/j.gendis.2021.08.006.

摘要

Abstract

Glioblastoma (GBM) is one of the most aggressive (grade IV) gliomas characterized by a high rate of recurrence

resistance to therapy and a grim survival prognosis. The long-awaited improvement in GBM patients’ survival rates essentially depends on advances in the development of new therapeutic approaches. Recent preclinical studies show that nanoscale materials could greatly contribute to the improvement of diagnosis and management of brain cancers. In the current review

we will discuss how specific features of glioma pathobiology can be employed for designing efficient targeting approaches. Moreover

we will summarize the main evidence for the potential of the IL-13R alpha 2 receptor (IL13α2R) targeting in GBM early diagnosis and experimental therapy.

关键词

Keywords

Brain tumorExperimental therapyGBMIL-13Rα2NanoparticlesReceptorViral vectors

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical applications of the CRISPR/Cas9 genome-editing system: Delivery options and challenges in precision medicine

Related Author

Mohadeseh Khoshandam

Hossein Soltaninejad

Marziyeh Mousazadeh

Amir Ali Hamidieh

Saman Hosseinkhani

Related Institution

Department of Reproductive Biology, Academic Center for Education, Culture, and Research (ACECR), Qom Branch, Qom 371698

National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran

Faculty of Interdisciplinary Science and Technology, Tarbiat Modares University, Tehran 6

Pediatric Cell and Gene Therapy Research Center, Gene, Cell & Tissue Research Institute, Tehran University of Medical Sciences, Tehran

Department of Nanobiotechnology, Faculty of Biological Sciences, Tarbiat Modares University, Tehran 6

⁰